Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

EU Bodies Agree Clearer Rules On Joint Procurement Of Vaccines & Treatments

Executive Summary

The new regulation on cross-border threats to health is the final part of the European Health Union, along with strengthened roles for the European Medicines Agency and the European Centre for Disease Prevention and Control. Its aim is to ensure collective EU action on preparedness, surveillance, risk assessment, and early warning and response in the event of health emergencies.

You may also be interested in...



New EU Body To Deal With COVID-19 Vaccine Strategy & Procurement

Europe is stepping up its efforts to prepare for future health crises. A new parliamentary committee will look at how to make the most of the lessons learned from the coronavirus pandemic, while EU health ministers will next week discuss “vaccine solidarity” and the draft regulation on cross-border threats to health.

EMA Begins Setting Up New Bodies To Tackle Drug Shortages

A new EU regulation has come into effect, giving the European Medicines Agency wider powers to monitor, prevent and manage shortages of medicines and medical devices in public health emergencies. A number of steering groups and other bodies and networks are being set up to put the new systems into action.

COVID-19: EU Under Pressure To Open Up On Vaccine Costs & Contracts

Transparency on COVID-19 vaccine funding, pricing and procurement is vital if vaccine hesitancy and disinformation are to be countered, say EU parliamentarians.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS146398

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel